Bristol-Myers Squibb: Philadelphia Chromosome trials

The registry lists 10 Philadelphia Chromosome studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 7Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCompletedNCT01030718Phase 1/2Results posted
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00982488Phase 2Results posted
• Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic StudyCompletedNCT00978731Phase 1Results posted
• A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid LeukemiaCompletedNCT00482703Phase 1/2Results posted
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCompletedNCT00481247Phase 3Results posted
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCompletedNCT00103844Phase 2Results posted
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to ImatinibCompletedNCT00101660Phase 2Results posted
• Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT03509896
• Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLWithdrawnNCT00349518Phase 2/3
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2